IRCT20091229002935N8招募中3 期
Spironolacton as adjunctive treatment of symptoms in patients with schizophrenia: a double blind and placebo controlled trial
Sanandaj University of Medical Sciences0 个研究点目标入组 52 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •Diagnosis of Schizophrenia based on DSM-5 criteria
- •Age between 18-55 years old
- •Chronic Schizophrenia- duration of the disorder more than 2 years
- •Minimum score of 20 in negative sub score
- •being stable on antipsychotic for the last 2 months(6 months for clozapine)
排除标准
- •Any serious medical or neurological problem
- •IQ less than 70.
- •Substance dependence during the last 6 months(except for nicotine and caffeine)
- •receiving ECT during the last 2 months
- •Acute or chronic systemic diseases
- •History of head trauma
- •exacerbation of symptoms(developing the active phase)
- •hypersensitivity to spironolacton
- •post-psychotic depression
- •gynecomastia
研究者
相似试验
招募中
3 期
The effect of spironolactone as adjunctive therapy on the improvement of cognitive symptoms and maniaBipolar disorderIRCT20190316043072N2Karaj University of Medical Sciences60
已完成
2 期
The Effect of Spironolactone in Treatment of Essential HypertensioHypertension.Essential (primary) hypertensionIRCT201502011525N6Shiraz University of Midical Sciences40
招募中
3 期
Effect of Spirinolactone in treatment of SchizophreniaSchizophrenia.SchizophreniaIRCT20090117001556N120Tehran University of Medical Sciences50
进行中（未招募）
1 期
Add-on spironolactone for the treatment of schizophreniaMedDRA version: 21.1Level: LLTClassification code 10039643Term: Schizophrenic psychosesSystem Organ Class: 100000004873SchizophreniaEUCTR2014-001968-35-DEKlinikum der Universität München - AöR vertreten durch den Vorstand des Bereiches umanmedizinH90
已完成
2 期
Add-on spironolactone for the treatment of schizophreniaF20SchizophreniaDRKS00008750Klinikum der Universität München, Campus Großhadern90